Syndax Pharmaceuticals has announced (pdf) it has secured $80 million in series C financing.
Syndax, based in Waltham, Mass., is a clinical stage biopharmaceutical company. It is developing entinostat, an investigational, targeted, epigenetic immunomodulator, as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer.
The financing round was led by Fidelity Management & Research Company and Delos Capital Fund. It involved participation with several other new and existing investors.
The company indicated the proceeds from the financing will go toward funding the continued development of entinostat.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.